Skip to main content

Advertisement

Table 2 Patient and tumour characteristics for the IBC series, (n) = number of patients. ER oestrogen receptor, PgR progesterone receptor, HR hormone receptor

From: Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression

Mean age (143) 60.1 years (25.7–91.2 years)
Mean sTIL score (106) 17.63%, 95% CI 15.00–20.26%
Menopausal status (142) Premenopausal 42 (29.4%)
Postmenopausal 101 (70.6%)
cN stage (142) 0 6 (4.2%)
1 53 (37.9%)
2 52 (37.1%)
3 29 (20.7%)
cM stage (143) 0 103 (72.0%)
1 40 (28.0%)
Pathological type (142) Ductal 134 (94.4%)
Lobular 5 (3.5%)
Mixed 3 (2.1%)
Differentiation (133) Grade 1 3 (2.3%)
Grade 2 35 (26.3%)
Grade 3 95 (71.4%)
ER (141) Negative 67 (47.5%)
Positive 74 (52.5%)
PgR (141) Negative 88 (62.4%)
Positive 53 (37.6%)
HER2+ (139) Negative 77 (55.4%)
Positive 62 (44.6%)
Molecular subtype (138) Luminal (HR+) 76 (55.1%)
HER2+ (HR-HER2+) 30 (21.7%)
TN (HR-HER2−) 32 (23.2%)
sTIL (106) < 10% 38 (35.8%)
≥ 10 to < 40% 54 (51.9%)
≥ 40% 13 (12.3%)
PD-L1 immune cells (105) < 1% 60 (57.1%)
≥ 1 to < 5% 28 (26.7%)
≥  5 to < 10% 13 (12.4%)
≥ 10% 4 (3.8%)